biostudies-literatureOstronoff FNCI NIH HHS1157-64https://www.ebi.ac.uk/biostudies/studies/S-EPMC4372852biostudies-literatureUnknown33(10)<h4>Purpose</h4>Younger patients with acute myeloid leukemia (AML) harboring NPM1 mutations without FLT3-internal tandem duplications (ITDs; NPM1-positive/FLT3-ITD-negative genotype) are classified as better risk; however, it remains uncertain whether this favorable classification can be applied to older patients with AML with this genotype. Therefore, we examined the impact of age on the prognostic significance of NPM1-positive/FLT3-ITD-negative status in older patients with AML.<h4>Patients and methods</h4>Patients with AML age ≥ 55 years treated with intensive chemotherapy as part of Southwest Oncology Group (SWOG) and UK National Cancer Research Institute/Medical Research Council (NCRI/MRC) trials were evaluated. A comprehensive analysis first examined 156 patients treated in SWOG triaJournal of clinical oncology : official journal of the American Society of Clinical OncologyPrognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.PMC4372852T32 CA009515CA12213N01 CA032102U10 CA180819N01 CA038926R01 CA160872U10 CA032102U10 CA073590U10 CA020319CA073590CA160872P01 CA018029U10 CA038926R01 CA114563R25 CA174664U10 CA180888CA20319U10 CA180828Othus MGodwin JStirewalt DLEstey EEvans ALazenby MPogosova-Agadjanyan ELOehler VGMeshinchi SGilkes ARadich JPWillman CLKopecky KJList AFBurnett AAppelbaum FROstronoff FFang MPetersdorf SHfalsePrognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.<h4>Purpose</h4>Younger patients with acute myeloid leukemia (AML) harboring NPM1 mutations without FLT3-internal tandem duplications (ITDs; NPM1-positive/FLT3-ITD-negative genotype) are classified as better risk; however, it remains uncertain whether this favorable classification can be applied to older patients with AML with this genotype. Therefore, we examined the impact of age on the prognostic significance of NPM1-positive/FLT3-ITD-negative status in older patients with AML.<h4>Patients and methods</h4>Patients with AML age ≥ 55 years treated with intensive chemotherapy as part of Southwest Oncology Group (SWOG) and UK National Cancer Research Institute/Medical Research Council (NCRI/MRC) trials were evaluated. A comprehensive analysis first examined 156 patients treated in SWOG tria2015-01-01T00:00:00Z2015 Apr2025-05-29T19:40:26.564Z2025-05-29T19:40:26.564ZS-EPMC43728522571343410.1200/jco.2014.58.057110.1200/JCO.2014.58.0571